Regen BioPharma Inc
OTC:RGBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Regen BioPharma Inc
Long-Term Investments
Regen BioPharma Inc
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Regen BioPharma Inc
OTC:RGBP
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Long-Term Investments
$665m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Investments
$268m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Long-Term Investments
$1.6B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-20%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Long-Term Investments
$2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Long-Term Investments
$2.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
Regen BioPharma Inc
Glance View
Regen Biopharma, Inc. is a biotechnology company, which focuses on the immunology and immunotherapy space. The company is headquartered in La Mesa, California and currently employs 1 full-time employees. The company went IPO on 2014-09-03. The firm is focused on immuno-oncology, stem cell/cancer stem cell, and gene silencing. The company is engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The firm focuses on the treatment of hematopoiesis (blood formation), breast cancer, liver cancer, leukemia, myelodysplastic syndrome, and aplastic anemia. The firm is also engaged in developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating molecular processes in cancer stem cell through its molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
